Raptor Pharmaceutical Corp. (NASDAQ:RPTP)’s share price was down 2.4% on Thursday . The company traded as low as $7.17 and last traded at $7.27, with a volume of 370,193 shares traded. The stock had previously closed at $7.45.

A number of equities analysts have recently weighed in on RPTP shares. Zacks Investment Research raised Raptor Pharmaceutical Corp. from a “hold” rating to a “buy” rating and set a $7.50 target price on the stock in a research report on Thursday, August 11th. Citigroup Inc. lowered Raptor Pharmaceutical Corp. from a “buy” rating to a “neutral” rating and upped their target price for the stock from $6.00 to $8.00 in a research report on Monday, August 8th. FBR & Co reaffirmed a “hold” rating and set a $10.00 target price on shares of Raptor Pharmaceutical Corp. in a research report on Tuesday, August 23rd. Cowen and Company reaffirmed a “buy” rating and set a $8.00 target price on shares of Raptor Pharmaceutical Corp. in a research report on Friday, August 19th. Finally, Wedbush reaffirmed a “neutral” rating and set a $4.00 target price on shares of Raptor Pharmaceutical Corp. in a research report on Friday, May 6th. Five investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $7.79.

The firm’s market capitalization is $621.03 million. The stock’s 50 day moving average is $6.62 and its 200 day moving average is $5.32.

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) last issued its quarterly earnings data on Thursday, August 4th. The company reported ($0.16) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.02. The business earned $32.05 million during the quarter, compared to the consensus estimate of $28.52 million. During the same quarter in the prior year, the business posted ($0.17) earnings per share. Raptor Pharmaceutical Corp.’s quarterly revenue was up 37.4% compared to the same quarter last year. On average, equities research analysts predict that Raptor Pharmaceutical Corp. will post ($0.91) earnings per share for the current year.

Raptor Pharmaceutical Corp. (Raptor) is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by diseases. Its product, PROCYSBI (cysteamine bitartrate) is a delayed-release capsules for the management of nephropathic cystinosis in adults and children of over six years.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.